EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Newer pharmacological interventions directed at gut hormones for obesity

Michael Camilleri, Andres Acosta

British Journal of Pharmacology · 2024-04 · 181 (8) · 1153-1164

DOI: 10.1111/bph.16278 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 30.11.2023. Verfasst von Michael Camilleri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Incretins, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective is to review the newer pharmacological interventions for obesity, specifically single, dual and triple incretin receptor agonists that are either available or in the pipeline for treatment of obesity. The three incretin receptor targets are glucagon like peptide‐1 (GLP‐1), glucose‐dependent insulinotropic peptide (GIP) and glucagon. There are several approved single or dual incretin agonists which can be administered subcutaneously daily (e.g., liraglutide) or weekly (e.g., semaglutide, dulaglutide, and exenatide QW), and other experimental dual or triple incretin agonists. Analogues of amylin, peptide YY and oxyntomodulin, as well as the combination of a GLP1R agonist and GIPR antagonist also are in development. Oral semaglutide (administered daily) is approved for type 2 diabetes mellitus and is on track for regulatory review for obesity. The review includes specifically perspectives on the effects of these mechanisms and pharmacological agents on gastric emptying, which contribute to satiation and weight loss, in addition to the established evidence on effects on central mechanisms controlling appetite. In the future, it is anticipated that small molecule GLP‐1 receptor agonists (e.g., oral danuglipron) will be developed for treating obesity. These pharmacological agents are having significant impact on glycaemic control and obesity and on their co‐morbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsDiabetes Mellitus, Type 2HumansObesityGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GIPGLP-1agonistsgluagonincretinsreceptors

Substanzen

IncretinsGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA.

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Camilleri, M., & Acosta, A. (2024). Newer pharmacological interventions directed at gut hormones for obesity. British Journal of Pharmacology, 181(8), 1153-1164. https://doi.org/10.1111/bph.16278

Vancouver

Camilleri M, Acosta A. Newer pharmacological interventions directed at gut hormones for obesity. British Journal of Pharmacology. 2024;181(8):1153-1164. doi:10.1111/bph.16278

BibTeX
@article{Camilleri2024,
  author = {Camilleri, Michael and Acosta, Andres},
  title = {Newer pharmacological interventions directed at gut hormones for obesity},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {8},
  pages = {1153--1164},
  doi = {10.1111/bph.16278}
}
Kostenlos starten →